The use of botulinum toxin type A in the treatment of bruxism

Bruxism is one of the most common myogenic disorders in the dental and jaw apparatus, which affects 6–20% of the world’s population, but 3–5% of the total number of patients have pronounced symptoms of this disease. The purpose of the study was to determine the effectiveness of the use of botulinum toxin type A in the treatment of bruxism as a primary aid in muscle relaxation. The presence of positive clinical effects from the use of botulinum therapy in the treatment of bruxism has been proven, namely: reduction of pain level according to the Visual Analogue Scale, normalization of muscle activity according to data of surface electromyography of temporal and masticatory muscles.

References

1. Lobbezoo F., Ahlberg J., Raphael K.G. et al. (2018) International consensus on the assessment of bruxism: Report of a work in progress. J. Oral Rehabil., 45: 837–844. doi: 10.1111/joor.12663.
2. Manfredini D., Serra-Negra J., Carboncini F., Lobbezoo F. (2017) Current Concepts of Bruxism. Int. J. Prosthodont., 30: 437–438. doi: 10.11607/ijp.5210.
3. Hosgor H., Altindis S. (2020) Efficacy of Botulinum Toxin in the Management of Temporomandibular Myofascial Pain and Sleep Bruxism. J. Korean Assoc. Oral Maxillofac. Surg., 46: 335–340. doi: 10.5125/jkaoms.2020.46.5.335.
4. Agren M., Sahin C., Pettersson M. (2020) The effect of botulinum toxin injections on bruxism: A systematic review. J. Oral Rehabil., 47: 395–402. doi: 10.1111/joor.12914.
5. Al-Wayli H. (2017) Treatment of chronic pain associated with nocturnal bruxism with botulinum toxin. A prospective and randomized clinical study. J. Clin. Exp. Dent., 9: e112–e117. doi: 10.4317/jced.53084.
6. Cheng Y., Yuan L., Ma L. et al. (2022) Efficacy of botulinum-A for nocturnal bruxism pain and the occurrence of bruxism events: a meta-analysis and systematic review. Br. J. Oral Maxillofac. Surg., 60: 174–182. doi: 10.1016/j.bjoms.2021.03.005.
7. Jadhao V., Lokhande N., Habbu S. et al. (2017) Efficacy of botulinum toxin in treating myofascial pain and occlusal force characteristics of masticatory muscles in bruxism. Indian J. Dent. Res., 28: 493. doi: 10.4103/ijdr.IJDR_125_17.
8. Muñoz Lora V.R.M., Del Bel Cury A.A., Jabbari B., Lacković Z. (2019) Botulinum Toxin Type A in Dental Medicine. J. Dent. Res., 98: 1450–1457. doi: 10.1177/0022034519875053.
9. Pardo N.B., Kerstein R.B., Júnior M.C. et al. (2022) Botulinum toxin type A for controlling bruxism assessed with computerized occlusal analysis: A pilot study. Cranio, 40: 207–216. doi: 10.1080/08869634.2020.1724458.
10. Yurttutan M.E., Tütüncüler Sancak K., Tüzüner A.M. (2019) Which Treatment Is Effective for Bruxism: Occlusal Splints or Botulinum Toxin? J. Oral Maxillofac. Surg., 77: 2431–2438. doi: 10.1016/j.joms.2019.06.005.